ReNeuron: biotech strategy and investor Q&A
7th February 2022 14:40
by Investor Meet Company from ii contributor
Chief executive officer Olav Hellebø and chief finance officer Catherine Isted of ReNeuron Group (LSE:RENE) present their strategic update and answer a range of investor questions. The event, held on 4 February 2022, is brought to you by our friends at Investor Meet Company.
Highlights
Q&A: 23:15
About the company:
ReNeuron Group PLC is a biotechnology firm and its core activities include the research and clinical development of cell-based therapeutics. The company product pipeline includes human retinal progenitor cell line (hRPC) and CTX neural cell line. It derives revenue from UK and US. The company is mainly focusing on the treatment of stroke disability, inherited retinal diseases, and cancer.
These articles are provided for information purposes only. Occasionally, an opinion about whether to buy or sell a specific investment may be provided by third parties. The content is not intended to be a personal recommendation to buy or sell any financial instrument or product, or to adopt any investment strategy as it is not provided based on an assessment of your investing knowledge and experience, your financial situation or your investment objectives. The value of your investments, and the income derived from them, may go down as well as up. You may not get back all the money that you invest. The investments referred to in this article may not be suitable for all investors, and if in doubt, an investor should seek advice from a qualified investment adviser.
Full performance can be found on the company or index summary page on the interactive investor website. Simply click on the company's or index name highlighted in the article.